These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37037186)

  • 1. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
    Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
    Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
    Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
    Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
    Rubbens J; Brouwers J; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
    Lloyd RS; Hingle MI; Bloomer JC; Charles SJ; Butler JM; Paul A; Zhu X; Miller B; D'Amico D; Donald A; Tal-Singer R; Ambery C
    Pharm Res; 2020 Oct; 37(12):233. PubMed ID: 33123802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
    Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
    J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
    Sharma S; Pepin X; Burri H; Zheng L; Kuptsova-Clarkson N; de Jong A; Yu T; MacArthur HL; Majewski M; Byrd JC; Furman RR; Ware JA; Mann J; Ramies D; Munugalavadla V; Sheridan L; Tomkinson H
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1294-1307. PubMed ID: 36029150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
    Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
    Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutic
    Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
    Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.
    Jones HM; Parrott N; Ohlenbusch G; Lavé T
    Clin Pharmacokinet; 2006; 45(12):1213-26. PubMed ID: 17112297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
    Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
    Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
    Moorthy G; Pouliot GP; Graham L; Pilling E; Jung L; Alcobi R; Zhu Y; Li Y; Sidhu S; Forte P; Mugundu G
    Br J Clin Pharmacol; 2023 Sep; 89(9):2775-2787. PubMed ID: 37055936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data.
    Fotaki N; Klein S
    Mol Pharm; 2013 Nov; 10(11):4016-23. PubMed ID: 23947755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.